A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab.
Current treatment options of essential mixed cryoglobulinemia (EMC); include immunosuppressive approaches, such as corticosteroids, cyclophosphamide, plasma exchange, other cytotoxic drugs in moderate to severe manifestations. Some controlled studies have been carried out to assess the efficacy of anti-CD20 monoclonal antibody, rituximab in patients with hepatitis C (HCV) related cryoglobulinemia (CG) and in patients with autoimmune disorders. Recent trials and some case reports demonstrate a beneficial role for rituximab in HCV related mixed CG. Although, the published evidence for treatment of EMC with rituximab is restricted to case reports, which have shown positive results. Several diseases include lymphoproliferative and myeloproliferative disorders, solid tumors, immunological disorders, cardiovascular disorders and some drugs associated with acquired von Willebrand disease (avWD). CG, which is a kind of immune complex disease, may be related with development of autoantibodies to various autoantigens. In this present case report, we showed the efficacy of rituximab in a 21-year-old female patient, suffered from neuropathy and arthralgia related with EMC, and developed avWD, presented with mucosal bleeding associated with CG. von Willebrand factor activity of our patient also increased with controlling the underlying disease, EMC by rituximab. This case demonstrate that rituximab may be an effective treatment option in EMC and avWD mainly related to CG.
Pasa
Semir
S
Department of Hematology, Medical Faculty, Dicle University, 21280 Diyarbakir, Turkey. semirpasa@dicle.edu.tr
Altintas
Abdullah
A
Cil
Timucin
T
Danis
Ramazan
R
Ayyildiz
Orhan
O
Muftuoglu
Ekrem
E
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018771:Arthralgia; D003449:Cryoglobulinemia / Q000150:complications* / Q000188:drug therapy*; D006470:Hemorrhage; D006801:Humans; D008297:Male; D000069283:Rituximab; D055815:Young Adult; D014842:von Willebrand Diseases / Q000188:drug therapy* / Q000209:etiology; D014841:von Willebrand Factor / Q000378:metabolism
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D014841:von Willebrand Factor; D000069283:Rituximab